New Alzheimers' treatment, Aducanumab, turns out to be just one more false hope for Alzheimer's patients
www.alzheimers-information.org
The new drug, Aducanumab, even as of today’s date, 28 December 2022, is heavily touted by the Alzheimer’s Association: [T]he first therapy to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer’s disease, from the brain is reasonably likely to reduce cognitive and functional decline in people living with early Alzheimer’s.
New Alzheimers' treatment, Aducanumab, turns out to be just one more false hope for Alzheimer's patients
New Alzheimers' treatment, Aducanumab, turns…
New Alzheimers' treatment, Aducanumab, turns out to be just one more false hope for Alzheimer's patients
The new drug, Aducanumab, even as of today’s date, 28 December 2022, is heavily touted by the Alzheimer’s Association: [T]he first therapy to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer’s disease, from the brain is reasonably likely to reduce cognitive and functional decline in people living with early Alzheimer’s.